Athersys Inc Overview
Industry: Biotechnology & Medical Research
Sector: Healthcare
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other co Read MoreAthersys Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Athersys Inc
Score
Recent News
Earnings Per Share
Score 3.00/5
Athersys Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
UnitedHealth Group Incorporated
IQVIA Holdings Inc
In
Biotechnology & Medical Research industry
, Syneos Health
, Krystal Biotech Inc
, Pluri Inc
are companies with high ratings.
Return on Equity
Score 0.17/5
Athersys Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
UnitedHealth Group Incorporated
IQVIA Holdings Inc
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
In
Biotechnology & Medical Research industry
, Syneos Health
, Krystal Biotech Inc
, Pluri Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
Net Margin
Score 0.68/5
Athersys Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
UnitedHealth Group Incorporated
IQVIA Holdings Inc
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
In
Biotechnology & Medical Research industry
, Syneos Health
, Krystal Biotech Inc
, Pluri Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
Leverage
Score 2.37/5
Athersys Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
UnitedHealth Group Incorporated
IQVIA Holdings Inc
have achieved high scores.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
In
Biotechnology & Medical Research industry
, Syneos Health
, Krystal Biotech Inc
, Pluri Inc
are companies with high ratings.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios
